TY - JOUR
T1 - Preferential solvation study of (Z)-N-benzyl-2-{5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl)acetamide (3) in {NMP (1) + Water (2)} co-solvent mixture and GastroPlus software based in vitro simulation
AU - Hussain, Afzal
AU - Afzal, Obaid
AU - Altamimi, Abdulmalik S.A.
AU - Ali, Abuzer
AU - Ali, Amena
AU - Martinez, Fleming
AU - Usman Mohd Siddique, Mohd
AU - Acree, William E.
AU - Ali, Naushad
N1 - Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - (Z)-N-benzyl-2-{5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl)acetamide (3) (SE11) is a newly synthesized benzylidine thiazolidinedione to inhibit aldose reductase (AR) to control Diabetes Mellitus (DM) and related complications. This reported compound exhibits poor water solubility and based on Hansen solubility parameter (HSP) considerations NMP (N-methyl-2-pyrrolidone) is expected to be a suitable co-solvent. SE11 was soluble in various ratios of (NMP + water) mixture at 298.15 K. Moreover, preferential-solvation (PS) of SE11 by the mixed components was investigated (thermodynamic functional parameters and Kirkwood-Buff integrals) followed by in-vitro dissolution, and simulation (GastroPlus) of dissolution data for the best fit of Weibull model. Hansen solubility parameters (HSP) analysis suggested NMP as the most relevant solvent for SE11 solubility at 298 K and predicted physicochemical properties. In PS, the molar-volume (214.0 cm3·mol−1), Hildebrand solubility parameter (31.11 MPa1/2), and molecular-radius (0.44 nm) of SE11 were calculated. The inverse Kirkwood-Buff integral computational analysis showed that the PS of SE11 through NMP was found in all explored ratios. The highest value (δx1,3 = 0.67 × 10–2) of PS was obtained at x1 = 0.60–0.65 in NMP. Finally, the GastroPlus software simulated in vitro dissolution profile and the impact of shape factor on release behaviour followed by computational assessment. Hence, the explored binary mixture can be used as a suitable approach to treat systemic DM.
AB - (Z)-N-benzyl-2-{5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl)acetamide (3) (SE11) is a newly synthesized benzylidine thiazolidinedione to inhibit aldose reductase (AR) to control Diabetes Mellitus (DM) and related complications. This reported compound exhibits poor water solubility and based on Hansen solubility parameter (HSP) considerations NMP (N-methyl-2-pyrrolidone) is expected to be a suitable co-solvent. SE11 was soluble in various ratios of (NMP + water) mixture at 298.15 K. Moreover, preferential-solvation (PS) of SE11 by the mixed components was investigated (thermodynamic functional parameters and Kirkwood-Buff integrals) followed by in-vitro dissolution, and simulation (GastroPlus) of dissolution data for the best fit of Weibull model. Hansen solubility parameters (HSP) analysis suggested NMP as the most relevant solvent for SE11 solubility at 298 K and predicted physicochemical properties. In PS, the molar-volume (214.0 cm3·mol−1), Hildebrand solubility parameter (31.11 MPa1/2), and molecular-radius (0.44 nm) of SE11 were calculated. The inverse Kirkwood-Buff integral computational analysis showed that the PS of SE11 through NMP was found in all explored ratios. The highest value (δx1,3 = 0.67 × 10–2) of PS was obtained at x1 = 0.60–0.65 in NMP. Finally, the GastroPlus software simulated in vitro dissolution profile and the impact of shape factor on release behaviour followed by computational assessment. Hence, the explored binary mixture can be used as a suitable approach to treat systemic DM.
KW - Computational studies
KW - Dissolution
KW - GastroPlus simulation studies
KW - HSPiP (Hansen solubility) software
KW - Preferential solvation
KW - SE11 in {NMP (1) + water (2)} mixture
UR - http://www.scopus.com/inward/record.url?scp=85123241961&partnerID=8YFLogxK
U2 - 10.1016/j.molliq.2022.118491
DO - 10.1016/j.molliq.2022.118491
M3 - Article
AN - SCOPUS:85123241961
SN - 0167-7322
VL - 349
JO - Journal of Molecular Liquids
JF - Journal of Molecular Liquids
M1 - 118491
ER -